Tirzepatide before and after 3 months: what does the evidence say?

How much weight do people typically lose in the first three months of tirzepatide?

Three months is roughly 13 weeks, which covers the starter period at 2.5 mg and usually one or two dose increases after that. In the SURMOUNT-1 trial, the sharpest early losses appeared in participants who reached higher doses, but even at 5 mg or 7.5 mg, which is where many people sit at the 12-week point, meaningful weight reduction was already visible. Extrapolating from the trial's trajectory, a realistic expectation at three months is somewhere in the 6–12% range for most people. Some will be above that; some below. The starter dose exists to give your body time to settle rather than to drive weight loss directly, so the first few weeks can feel slow before things pick up.

A question our prescribers hear most weeks is: "I've only lost a few kilograms, is that normal?" The honest answer is yes, for someone who started relatively recently. The timeline for Mounjaro to show results follows a curve, not a straight line, and early losses are partly masking even more change happening at the metabolic level.

If you're curious how the picture changes over a longer stretch, the six-month tirzepatide results page covers what the trial data shows once people are consistently on maintenance doses.

What changes (besides the number on the scales) by month three?

The before-and-after picture at three months isn't only about weight. Appetite tends to shift noticeably within the first few weeks: meals that felt necessary become easier to leave unfinished, and the mental background noise of thinking about food between meals often quietens. People frequently describe this as one of the most significant early changes, because it's a lived experience that the scales don't capture.

Clothing fit is another early marker. Fat loss tends to come from the abdomen first, which means trouser waistbands and shirt buttons often register a change before a big movement on the scales. Energy levels can improve too, particularly for people whose weight had been affecting sleep or joint comfort.

Blood pressure, blood glucose markers and cholesterol can begin shifting within three months as well, though how much depends on where they started and what dose someone has reached. These changes are part of why tirzepatide is licensed not just for weight management but also for type 2 diabetes, the mechanism that slows gastric emptying and supports better glucose regulation doesn't switch off while you're losing weight. You can read a fuller overview of how the medicine works on the Mounjaro treatment page.

Is three months enough to judge whether tirzepatide is working?

Three months is a reasonable early check-in, but it's not a final verdict. NICE's recommendation for tirzepatide (set out in technology appraisal TA1026) notes that continuing treatment should be reviewed if less than 5% weight loss is achieved after six months at the highest tolerated dose. That threshold is set at six months, not three, deliberately. Bodies respond to tirzepatide at different speeds, and someone who has lost 4% at three months may reach 10% by month six as their dose increases.

That said, three months without any change at all (no shift in appetite, no movement on the scales, no non-scale changes) is worth discussing with your prescriber. It may indicate that a dose adjustment is due, that the medicine isn't the right fit, or that something in the treatment plan needs revisiting.

For a broader look at the evidence across timepoints, the full tirzepatide before-and-after overview pulls together what the data shows at each stage. And if the one-month mark is where you currently are, the first-month results page sets realistic early expectations before the dose has had a chance to build.

Cost is a practical part of any three-month treatment journey. Prices in the private market have shifted considerably since Eli Lilly revised its UK list pricing, the full context on that price change is worth reading if you're planning ahead.

How do tirzepatide's three-month results compare with semaglutide at the same point?

Direct head-to-head comparisons at the specific three-month mark are limited, but the broader SURMOUNT-5 trial (published in the New England Journal of Medicine in 2025) showed that tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity. Earlier in treatment, the gap between the two medicines tends to be smaller, partly because both start at tolerability doses and titrate gradually. By three months, if someone has reached a mid-range dose of tirzepatide (say 7.5 mg) and a mid-range dose of semaglutide, the practical difference is unlikely to be dramatic. The divergence becomes clearer at higher doses over longer treatment periods.

The distinction between these medicines and what suits a particular person is a clinical question, one worth exploring with a prescriber rather than settling on the basis of trial averages alone. The Mounjaro before and after three months page covers the same timeframe using the brand name most people in the UK will recognise.